Virginia Tech Offers Biotechnology 2001 Conference for Educators

May 22, 1998

(Blacksburg, VA, May 22, 1998) -- Nobel Laureate Kary Mullis and mammalian cloning pioneer Keith Campbell will be among the presenters at the Biotechnology 2001 Conference on Friday, June 26 at Virginia Tech.

The event is organized by the university's Fralin Biotechnology Center and Division of Continuing Education, in collaboration with the National Association of Biology Teachers to help science educators keep abreast of scientific discoveries and related developments in biotechnology. High school and community college faculty members as well as other interested persons are encouraged to attend.

Saturday, June 27 features 20 workshops with an array of innovative activities for the high school and community college classroom or laboratory.

Friday's program also offers several other outstanding scientists.

Carole Cramer, Virginia Tech professor of plant pathology, physiology and weed science and vice president of research with Croptech Development Corporation of Blacksburg, will talk about "Transgenic Plants for Human Pharmaceutical and Vaccine Production."

"Gene Therapy and Gene Repair" is the topic of a talk by Ken Culver, director of gene therapy research at Codon Pharmaceuticals of Gaithersburg, Md.

Terry Sharrer, curator of health sciences at the Smithsonian, will talk about "Cancer History and Gene Therapy Trials."

David Magnus of the Center for Bioethics at the University of Pennsylvania will address "Bioethical Implications of Mammalian Cloning."

And Paula Gregory-Division of Human Cancer Genetics, Ohio State University, will talk about "The Human Genome Project and Its Impact on Medicine."

Workshops, which are available to high school teachers, community college, and college faculty only, include programs by scientists from school and public and private laboratories around the country.

The registration fee for the conference is $120. This fee includes refreshment breaks, lunch and barbecue on Friday, handouts, lectures and workshops (for high school and community college faculty and subject to workshop size limits). The full-time student fee is $25 for Friday speakers only (lunch not included). After June 5, the registration fee is $140 and should be confirmed by phone with the Conference Registrar at 540-231-5182.

Lodging is offered at the hotel on campus or in one of the dormitories. Call the hotel, 540-231-5156, or dorm and dining services, 540-231-4849, by May 26 for reservations.
For further assistance send an inquiry to or

Contact for further information
Don Ball
Fralin Biotechnology Center
540-231-7126 fax

Conference Program:
On-line registration:

Virginia Tech

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to